230 related articles for article (PubMed ID: 21844831)
1. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
Lapham SC; McMillan GP
J Addict Med; 2011 Sep; 5(3):163-9. PubMed ID: 21844831
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
O'Malley SS; Garbutt JC; Gastfriend DR; Dong Q; Kranzler HR
J Clin Psychopharmacol; 2007 Oct; 27(5):507-12. PubMed ID: 17873686
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
4. Extended-release naltrexone for treatment of alcohol dependence in primary care.
Lee JD; Grossman E; DiRocco D; Truncali A; Hanley K; Stevens D; Rotrosen J; Gourevitch MN
J Subst Abuse Treat; 2010 Jul; 39(1):14-21. PubMed ID: 20363090
[TBL] [Abstract][Full Text] [Related]
5. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.
Lapham S; Forman R; Alexander M; Illeperuma A; Bohn MJ
J Subst Abuse Treat; 2009 Jan; 36(1):1-6. PubMed ID: 18775624
[TBL] [Abstract][Full Text] [Related]
6. Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.
Lee JD; Grossman E; Huben L; Manseau M; McNeely J; Rotrosen J; Stevens D; Gourevitch MN
J Subst Abuse Treat; 2012 Dec; 43(4):458-62. PubMed ID: 22985676
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.
Finigan MW; Perkins T; Zold-Kilbourn P; Parks J; Stringer M
J Subst Abuse Treat; 2011 Oct; 41(3):288-93. PubMed ID: 21696912
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Galloway GP; Koch M; Cello R; Smith DE
BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
[TBL] [Abstract][Full Text] [Related]
9. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
Lucey MR; Silverman BL; Illeperuma A; O'Brien CP
Alcohol Clin Exp Res; 2008 Mar; 32(3):498-504. PubMed ID: 18241321
[TBL] [Abstract][Full Text] [Related]
10. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
11. Sustained-release naltrexone for alcoholism treatment: a preliminary study.
Kranzler HR; Modesto-Lowe V; Nuwayser ES
Alcohol Clin Exp Res; 1998 Aug; 22(5):1074-9. PubMed ID: 9726277
[TBL] [Abstract][Full Text] [Related]
12. Early treatment response in alcohol dependence with extended-release naltrexone.
Ciraulo DA; Dong Q; Silverman BL; Gastfriend DR; Pettinati HM
J Clin Psychiatry; 2008 Feb; 69(2):190-5. PubMed ID: 18348601
[TBL] [Abstract][Full Text] [Related]
13. The alcohol interlock: an underutilized resource for predicting and controlling drunk drivers.
Marques PR; Tippetts AS; Voas RB
Traffic Inj Prev; 2003 Jan; 4 Suppl 1():5-11. PubMed ID: 16801123
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study.
Yoon G; Kim SW; Thuras P; Westermeyer J
Hum Psychopharmacol; 2011 Mar; 26(2):125-32. PubMed ID: 21437991
[TBL] [Abstract][Full Text] [Related]
15. Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking.
Hernandez-Avila CA; Song C; Kuo L; Tennen H; Armeli S; Kranzler HR
Alcohol Clin Exp Res; 2006 May; 30(5):860-5. PubMed ID: 16634855
[TBL] [Abstract][Full Text] [Related]
16. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
17. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
[TBL] [Abstract][Full Text] [Related]
18. Long-acting injectable naltrexone for the treatment of alcohol dependence.
Mannelli P; Peindl K; Masand PS; Patkar AA
Expert Rev Neurother; 2007 Oct; 7(10):1265-77. PubMed ID: 17939765
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.
Monti PM; Rohsenow DJ; Swift RM; Gulliver SB; Colby SM; Mueller TI; Brown RA; Gordon A; Abrams DB; Niaura RS; Asher MK
Alcohol Clin Exp Res; 2001 Nov; 25(11):1634-47. PubMed ID: 11707638
[TBL] [Abstract][Full Text] [Related]
20. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.
Springer SA; Di Paola A; Azar MM; Barbour R; Krishnan A; Altice FL
Drug Alcohol Depend; 2017 May; 174():158-170. PubMed ID: 28334661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
